



JPW

Attorney Docket: UNI.26

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: JIA) EXAMINER: WINSTON, R.
SERIAL NUMBER: 10/817,330) ART UNIT: 1655
FILING DATE: APRIL 2, 2004)
TITLE: FORMULATION OF DUAL)
CYCLOXYGENASE (COX))
AND LIPOXYGENASE)
(LOX) INHIBITORS FOR)
MAMMAL SKIN CARE)

Mail Stop:
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application. In accordance with 37 CFR § 1.98(a)(3)(ii), an English translation of the abstract for Chinese Patent Publication Number CN1096680A and an English translation of the abstract for Chinese Patent Publication Number CN1285202A are provided.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

37 CFR 1.8
CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on 19 SEPTEMBER 2005.


Signature: 

Name: Lisa S. Susser

No fee is believed to be due in this instance. The undersigned hereby authorizes the charge of any deficiency of fees submitted herewith, or the credit of any overpayment, to deposit account number 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,


Rosemary Kellogg, #39,726
Swanson & Bratschun, LLC
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
303.268.0066
303.268.0065 (FAX)

cc: Unigen Pharmaceuticals, Inc.

S:\CLIENTFOLDERS\UNIGEN PHARMACEUTICALS\UNI26\UTILITY\IDS06.DOC

FORM PTO-1449

US DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK
OFFICE

ATTORNEY DOCKET NUMBER

SERIAL NUMBER

UNI.26

10/817,330

APPLICANT

JIA

FILING DATE


APRIL 2, 2004

GROUP ART UNIT

1655

List of Information Cited by Applicant

Page 1 of 1



US PATENT DOCUMENTS

EXAM INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUBCLS	FILE DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						
	AR						

FOREIGN PATENT DOCUMENTS

EXAM INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUBCLS	TRANS?
	AS	CN1096680A	DEC. 28, 1994	CHINA			
	AT	CN1285202A	FEB. 28, 2001	CHINA			
	AU						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AV	Butenko et al. (1993) Agents Actions Special Conference Issue 39:C49-C51
	AW	Kikukawa et al. (1995) Ensho 15(2):129-33 (Abstract)
	AX	Kubo et al. (1984) Chemical and Pharmaceutical Bulletin 32(7):2724-2729
	AY	Yamahara et al. (1981) Shoyakugaku Zasshi 35(2):103-107 (Abstract)
	AZ	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.